Choices Among Immunotherapeutics May Be the Future of Lung Cancer Care

Novel immunotherapy agent atezolizumab (MPDL3280A) looks superior to Taxotere (docetaxel) in a study, specifically for patients with PD-L1. What are the implications of multiple agents with similar me... Author: cancergrace Added: 06/26/2015
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts